Endocyte, Inc. (NASDAQ:ECYT) and Merck & Co. (MRK: Quote) announced Friday morning that the Data Safety Monitoring Board of the PROCEED trial has recommended that the trial be stopped because vintafolide did not demonstrate efficacy on the pre-specified outcome of Progression-Free Survival in patients with platinum-resistant ovarian cancer. Endocyte, Inc. (NASDAQ:ECYT), shares after opening at $6.75 moved to $7.05 on last trade day and at the end of the day closed at $6.62. Company price to sales ratio in past twelve months was calculated as 4.22 and price to cash ratio as 2.22. Endocyte, Inc. (NASDAQ:ECYT), showed a negative weekly performance of 63.10%.
On May 01, 2014, Cerus Corporation (NASDAQ:CERS), announced financial results for the first quarter ended March 31, 2014. Cerus Corporation (NASDAQ:CERS), shares fell 11.93% in last trading session and ended the day on $3.84. Cerus Corporation (NASDAQ:CERS), return on equity ratio is recorded as -89.40% and its return on assets is -51.40%. Cerus Corporation (NASDAQ:CERS), yearly performance is -20.82%.
On April 30, 2014, XenoPort, Inc. (NASDAQ:XNPT), announced that it will present new analyses of data for gabapentin enacarbil (GEn), the active ingredient in HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets, at the 33(rd) Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida. XenoPort, Inc. (NASDAQ:XNPT), shares moved down 4.04% in last trading session and was closed at $3.80, while trading in range of $ 3.78 – 3.99. XenoPort, Inc. (NASDAQ:XNPT), year to date (YTD) performance is -33.91%.
On May 01, 2014, Therapies Inc (NASDAQ:VTL), a biotherapeutic companydeveloping a cell-based therapy targeting the treatment of acuteliver failure, announced that the 100th subject has beenenrolled in VTI-208, a Phase 3 randomized, controlled clinical trialin 200 subjects with alcohol-induced liver decompensation, or AILD. Vital Therapies Inc (NASDAQ:VTL), weekly performance is -9.52%. On last trading day company shares ended up $11.21. Vital Therapies Inc (NASDAQ:VTL), distance from 50-day simple moving average (SMA50) is -9.75%.